Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 585

1.

Triple uptake inhibitors: therapeutic potential in depression and beyond.

Chen Z, Skolnick P.

Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77. Review.

PMID:
17714023
2.

Milnacipran and selective serotonin reuptake inhibitors in major depression.

Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6. Review.

PMID:
8923126
3.

Designing new treatments for depression and anxiety.

Chen Z, Yang J, Tobak A.

IDrugs. 2008 Mar;11(3):189-97. Review.

PMID:
18311656
4.

Current trends in the development of new antidepressants.

Pacher P, Kohegyi E, Kecskemeti V, Furst S.

Curr Med Chem. 2001 Feb;8(2):89-100. Review.

PMID:
11172668
5.
6.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
7.

[The effectiveness of antidepressants in the treatment of chronic non-cancer pain--a review].

Miller A, Rabe-Jabłońska J.

Psychiatr Pol. 2005 Jan-Feb;39(1):21-32. Review. Polish.

PMID:
15771151
8.

Pharmacology of antidepressants: selectivity or multiplicity?

Westenberg HG.

J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. Review.

9.

Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants.

Mukai Y, Tampi RR.

Clin Ther. 2009 May;31(5):945-61. doi: 10.1016/j.clinthera.2009.05.016. Review.

PMID:
19539096
10.
11.

[Neurobiology and pharmacotherapy of social phobia].

Aouizerate B, Martin-Guehl C, Tignol J.

Encephale. 2004 Jul-Aug;30(4):301-13. Review. French.

PMID:
15538306
12.

Duloxetine pharmacology: profile of a dual monoamine modulator.

Karpa KD, Cavanaugh JE, Lakoski JM.

CNS Drug Rev. 2002 Winter;8(4):361-76. Review.

13.

Dual monoamine modulation for improved treatment of major depressive disorder.

Tran PV, Bymaster FP, McNamara RK, Potter WZ.

J Clin Psychopharmacol. 2003 Feb;23(1):78-86. Review. Erratum in: J Clin Psychopharmacol. 2003 Aug;23(4):425.

PMID:
12544378
15.

The dual-action hypothesis: does pharmacology matter?

Shelton RC.

J Clin Psychiatry. 2004;65 Suppl 17:5-10. Review.

16.

Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

Ruhé HG, Huyser J, Swinkels JA, Schene AH.

J Clin Psychiatry. 2006 Dec;67(12):1836-55. Review.

PMID:
17194261
17.

SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.

Stahl SM, Grady MM, Moret C, Briley M.

CNS Spectr. 2005 Sep;10(9):732-47. Review.

PMID:
16142213
18.

Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.

Butler SG, Meegan MJ.

Curr Med Chem. 2008;15(17):1737-61. Review.

PMID:
18673223
19.

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, Richelson E.

Eur J Pharmacol. 2007 Jan 19;555(1):30-6. Epub 2006 Oct 17.

PMID:
17109850
20.

Pharmacological principles of antidepressant efficacy.

Schatzberg AF.

Hum Psychopharmacol. 2002 Jun;17 Suppl 1:S17-22. Review.

PMID:
12404665

Supplemental Content

Support Center